REG - Tissue Regenix Group - Further re. financial update and funding plans

Tissue RegenixAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251201:nRSA6088Ja&default-theme=true

RNS Number : 6088J  Tissue Regenix Group PLC  01 December 2025

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

 

Further re. financial update and funding plans

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides
a further update to its financial position.

 

Further to the announcement of 7 November 2025, the Senior Leadership Team
continues to clarify the immediate funding needs of the business and the
larger capital sum needed to restore revenue growth. The Company has secured
an emergency overdraft of $500K from MidCap, its existing lender, which has
allowed Tissue Regenix to make November payroll and remain solvent. The
Company remains in dialogue with its major shareholders with respect to its
short- and medium-term funding requirement and expects to provide a further
update and post a circular to shareholders later this week.

 

The Company still expects to raise funds by way of a convertible loan note and
will provide an update in due course. Any fundraise will be subject to
shareholder approval.

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Jay LeCoque, Executive Chairman                            via Walbrook PR

 Cavendish Capital Markets (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                     Tel: +44 (0) 20 7466 5000

 Nigel Birks - Life Science Specialist Sales

 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                          Tel: +44 (0)20 7933 8780
 Alice Woodings / Lianne Applegarth                         Tissue Regenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

 

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURBIBDBGUXDGUG



            Copyright 2019 Regulatory News Service, all rights reserved